<DOC>
	<DOCNO>NCT00454298</DOCNO>
	<brief_summary>The main purpose study find , 4 week dose , sign investigational drug AGG-523 , effect , measure urine , blood , knee joint . A secondary purpose evaluate safety take drug either day twice day 4 week .</brief_summary>
	<brief_title>Study Evaluating AGG-523 Subjects With Severe Osteoarthritis Requiring Total Knee Replacement</brief_title>
	<detailed_description>This multicenter study 2 dose regimen AGG-523 , investigational aggrecanase inhibitor take orally . Potential study subject severe Osteoarthritis ( OA ) knee schedule undergo total joint replacement surgery . Study subject randomly assign 1 2 dosing regimen ( once-daily twice-daily dose ) either 1800 mg AGG-523 placebo , take 4-week period total knee replacement . The treatment assign use 4:1 ratio active placebo treatment , mean subject receive active treatment placebo ( see ) . - AGG-523 1800 mg day ( 32 subject ) - AGG-523 900 mg twice day ( 32 subject ) - Placebo day ( 8 subject ) - Placebo twice day ( 8 subject ) Study subject weekly evaluation outpatient 4-week dosing period . The purpose evaluation monitor potential complication , ensure compliance take study drug , ask use medication , , necessary , replenish supply study drug . These assessment may conduct telephone , home visit , subject travel clinic outpatient office visit . A final ( person ) visit happen 2 week total knee replacement surgery .</detailed_description>
	<mesh_term>Osteoarthritis</mesh_term>
	<criteria>Generally healthy , men woman , least 55 year old Osteoarthritis knee require total knee replacement surgery Other type arthritis , like rheumatoid arthritis Recent major surgery ( past 3 month ) Recent knee injection ( past 6 month )</criteria>
	<gender>All</gender>
	<minimum_age>55 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2009</verification_date>
	<keyword>Severe Osteoarthritis</keyword>
	<keyword>Arthritis</keyword>
</DOC>